DJS Law Group says Insulet faces securities class action over manufacturing claims
DJS Law Group says investors who bought Insulet shares during the stated class period may contact the firm after a securities class action was filed over alleged market misstatements.
DJS Law Group says it is notifying investors about a class action lawsuit against Insulet Corporation, alleging the medical device maker violated federal securities laws through statements about its manufacturing processes and related safety risks.
The release says the case involves shareholders who bought Insulet stock during the stated class period because it seeks recovery for alleged losses tied to the company’s public statements. It also says lead plaintiff status is not required to take part in any recovery.
According to the release, the lawsuit cites Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. It identifies Insulet, which trades on Nasdaq under the ticker PODD, and says the class period runs from Feb. 21, 2025, to May 26, 2026.
The press release alleges Insulet made false and misleading statements to the market, failed to maintain appropriate controls over its manufacturing processes, and that those manufacturing problems created safety risks for customers. The source does not include an underlying complaint, court, case number or judge.
The release is dated Aug. 3, 2026, and datelined Los Angeles. It says shareholders who purchased PODD shares during the class period are encouraged to contact DJS Law Group about possible lead plaintiff appointment.
The contact listed is David J. Schwartz of DJS Law Group in Eastchester, New York, with a phone number and email address provided in the release.
The release says investors can seek information from DJS Law Group if they believe they were affected.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.